Lilly migraine drug wins European panel thumbs-up [Reuters]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Reuters
Lilly migraine drug wins European panel thumbs-up | Reuters 1 Min Read Sept 21 (Reuters) - A European Medicines Agency panel on Friday recommended the approval of U.S. pharmaceutical group Eli Lilly’s migraine treatment, bringing the drug one step closer to being sold in the European Union. Emgality, or galcanezumab, which treats episodic cluster headache attacks, was endorsed by the Committee for Medicinal Products for Human Use, a panel whose recommendations are generally followed by European regulators. Emgality targets a protein associated with pain-signalling, called calcitonin gene-related peptide, or CGRP. Lilly’s drug belongs to a new class of drugs targeting CGRP to treat migraines. Amgen, Teva and Allergan are also developing similar medicines. Israel-based Teva received the U.S. Food and Drug Administration’s (FDA) approval for its new migraine drug, Ajovy, last week. The FDA is expected to decide on Lilly’s drug by Sept. 27. (Reporting by Arathy S Nair in Bengaluru; Editin
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Top Research Reports for Eli Lilly, Linde & Caterpillar [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show [Yahoo! Finance]Yahoo! Finance
- Almost Every Dose of Lilly's Zepbound Is in Shortage, FDA Says [BNN Bloomberg (Canada)]BNN Bloomberg
- UPDATE 1-Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says [Yahoo! Finance]Yahoo! Finance
- Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says [Reuters]Reuters
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website